A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours

Advanced Tumours Clinical Trial

Official title:
A Phase I/II, First-in-Human, Open-Label, Dose-Escalation and Dose-Extension Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours

Status Terminated

Clinical Trial Summary

This is a phase I/II, open-label, dose escalation and dose extension study to evaluate the safety, tolerability, PK, and preliminary efficacy of LM-061 in subjects with advanced tumors.

Clinical Trial Description

This is a phase I/II, open-label, dose escalation and dose extension study to evaluate the safety, tolerability, PK, and preliminary efficacy of LM-061 in subjects with advanced tumors. The study schedule includes screening visit (28 days prior to accept the investigational medicinal product (IMP)), treatment visit (accept IMP for the first time to the end of treatment (EOT)/early withdrawal), and follow-up visit (28 days after the EOT/early withdrawal). ;

Study Design

Related Conditions & MeSH terms

Advanced Tumours

Clinical Trial Details

NCT number	NCT04882176
Study type	Interventional
Source	LaNova Medicines Limited
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	May 20, 2021
Completion date	July 19, 2023

View Details

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT04737122` - Study of LM-061 in Subjects in Advanced Tumors	Phase 1
	Active, not recruiting	`NCT01078662` - Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats	Phase 2